MiMedx-Sanara Merger Faces Fresh Regulatory Obstacle – SMTI Stock Falls Below This Key Support Level For The First Time In 4 Months

The FTC issued a Second Request for more information on MiMedx's (MDXG) acquisition of Sanara (SMTI), delaying the merger beyond the year-end target. SMTI shares fell 5.5%, dropping below their 50-day moving average, while MDXG shares declined 2.8%. The deal, valued at $35 per share, aims to create a larger regenerative medicine company with $400M revenue expected in FY2027.

Original reporting
Published Oct 16, 2026, 5:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 5:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
MiMedx-Sanara Merger Faces Fresh Regulatory Obstacle – SMTI Stock Falls Below This Key Support Level For The First Time In 4 Months — source image
Decision brief

The 30-second read

$SMTIBearishMed
01

Why it matters

The FTC issued a Second Request, which extends the mandatory waiting period to 30 days after both companies comply, pushing the timeline beyond the original year-end target and driving a same-day selloff in both merger partners.

02

Market read

This is a direct, deal-specific antitrust procedural update that changes expected closing timing and increases uncertainty for both counterparties.

03

What to watch

The article does not quantify compliance progress or any remedies; traders may be over-weighting timeline risk versus deal probability if filings are already underway.

Relevance 8/10Novelty 7/10Timing: today, after-hours/next-session repricing of FTC Second Request deal-timing risk

Background

MiMedx agreed in July to acquire Sanara in a cash-and-stock deal at $35 per share, targeting year-end close.

Company-level read

Ticker impact

$SMTIBearishHigh confidence
Context

Sanara MedTech shares fell after the FTC issued a Second Request for the MiMedx-Sanara merger, extending the waiting period by 30 days.

Expected impact

Likely downside bias as traders price a longer timeline and higher deal-risk premium.

Evidence & confidence

The article ties SMTI’s drop to the FTC Second Request and explicitly notes the waiting period extension beyond the original year-end target.

$MDXGBearishHigh confidence
Context

MiMedx Group shares also dropped as the FTC Second Request seeks additional documents for the proposed merger with Sanara, delaying closure.

Expected impact

Likely continued weakness or volatility as the market reprices the probability/timing of completion.

Evidence & confidence

The text links MDXG’s move directly to the FTC Second Request and the resulting 30-day extension after compliance.

Market effects

Adds regulatory overhang risk for regenerative medicine M&A, potentially raising perceived antitrust friction for similar deals.

Limited, primarily affects US-listed merger counterparties and biotech/regenerative-medicine sentiment.

Low, as the catalyst is a US FTC antitrust process for specific companies.

Counterpoint

A Second Request does not imply rejection; if both firms promptly comply, the deal can still close, limiting long-term downside.

Key entities

  • MiMedx Group

    US-listed acquirer in the proposed regenerative medicine merger with Sanara.

  • Sanara MedTech

    US-listed target in the proposed regenerative medicine merger with MiMedx.

  • Federal Trade Commission (FTC)

    Issued a Second Request for additional documents in the antitrust review.

Related articles

$SMTIMed

Sanara MedTech Inc. Reports Third Quarter 2026 Financial Results (Unaudited)

Sanara MedTech Inc. (SMTI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sanara MedTech Inc. Reports Third Quarter 2026 Financial Results (Unaudited) FORT WORTH, TX, November 12, 2026 (GLOBE NEWSWIRE) — Sanara MedTech Inc. (“Sanara,” “Sanara MedTech,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused

$MDXGMed

MiMedx Group Inc (MDXG) (Q3 2026) Earnings Call Highlights: Revenue Jumps 36%

MiMedx Group Inc (MDXG) reported a 36% revenue jump in Q3 2026. CFO Danilo D'Alessandro expects gradual reduction in cash burn over the next four to six quarters. CEO Joe Burnett highlighted growth opportunities in spine laser therapy, with estimated revenue of $13,000 to $20,000 per procedure. The company aims for mid-teens growth in 2027, with guidance expected in January. MDXG also discussed investments in robotics and focused ultrasound, and the status of the UniQure AMT-130 BLA submission.

$MDXGMed

MiMedx (MDXG) Q3 2026 Earnings Call Transcript

MiMedx (MDXG) reported Q3 2026 net sales of $62M, with Surgical revenue up 9% YoY and Wound Care Center volume up 7% sequentially. The company expects to complete the Sanara MedTech acquisition, pending FTC approval, aiming for $400M in combined revenue and 20% adjusted EBITDA margin. MiMedx also won a court ruling against the FDA's classification of AXIOFILL and reached a $25M settlement in a patent infringement case.

$MDXGHighAI 8/10

What MiMedx Group (MDXG) Said on Its Q3 Earnings Call

MiMedx Group (MDXG) reported Q3 earnings with gross profit of $50M, down from $95M YoY, and a GAAP net loss of $9M. Wound care volume rose 20% YoY, but margins declined due to pricing and product mix. The company expects 2027 conditions to persist and anticipates modest EBITDA growth in Q4. MiMedx is acquiring Sanara MedTech, facing FTC review, aiming for $400M revenue and 20% EBITDA margin post-merger. Legal and product updates include a $25M settlement and progress on 510(k) submissions.

$MDXGMed

MiMedx: Q3 Earnings Snapshot

MiMedx Group Inc. (MDXG) reported a Q3 loss of $8.7 million, or 6 cents per share, with adjusted losses of 1 cent per share. Revenue was $62.3 million. The company expects full-year revenue between $250 million and $260 million, according to its earnings release.